| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | — | +91.0% |
| R&D Expense | $20.4M | — | +83.7% |
| SG&A Expense | $7.7M | — | +14.0% |
| Operating Income | -$25.4M | — | -54.3% |
| Net Income | -$22.3M | — | -72.1% |
| EPS (Basic) | -$0.52 | — | -44.4% |
| EPS (Diluted) | -$0.52 | — | -44.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $241.8M | +28.0% | -6.1% |
| Short-term Investments | $141.4M | +53.4% | +124.4% |
| Accounts Receivable | $709K | -7.8% | +96.4% |
| Current Assets | $391.9M | +36.6% | +20.6% |
| Total Assets | $397.7M | +34.8% | +15.7% |
| Current Liabilities | $15.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$24.0M | — | -38.5% |
| Capital Expenditures | $26K | — | -93.9% |
| Investing Cash Flow | -$46.8M | — | +40.1% |
| Financing Cash Flow | $123.7M | — | +8347.7% |
| Free Cash Flow | -$24.1M | — | -35.3% |
| -33.3% |
| Total Liabilities | $18.5M | -18.9% | -39.6% |
| Stockholders' Equity | $379.1M | +39.4% | +21.1% |